Fig. 3

Fc-μTP-L309C, IVIg and SCIg can prevent arthritis in both the endogenous and in the serum transfer model. The clinical scores (a) are shown for mice treated with 11 injections of IVIg, SCIg or Fc-μTP-L309C. Injections were given on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21. Shown are the average clinical scores; error bars indicate range of clinical scores (mean ± SD; n = 6 for each treatment group). ***P < 0.0001 2000 mg/kg IVIg vs. HSA, 2000 mg/kg SCIg vs. HSA and 200 mg/kg Fc-μTP-L309C vs. HSA. Similar results were obtained in two independent experiments. The clinical scores (b) are shown for BALB/c mice given i.p. injections of 200 μl of arthritic serum on days 0 and 2, indicated by ^, that were treated with 2 g/kg of IVIg or SCIg or with 200 mg/kg of Fc-μTP-L309C on day 2, indicated by arrow, in comparison to mice treated with HSA. Shown are the average clinical scores; error bars indicate range of clinical scores (mean ± SD; n = 5 for each treatment group). ***P < 0.0001 2000 mg/kg IVIg vs. HSA, 2000 mg/kg SCIg vs. HSA and 200 mg/kg Fc-μTP-L309C vs. HSA